Precigen returns to profit in Q2 FY26; revenue rises to $54.98 million

Reuters2026/08/04 20:42

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Precigen swung to net income of $20.07 million on revenue of $54.98 million in Q2 2026, from a net loss of $26.64 million on revenue of $856,000.
Operating income was $22.64 million, versus an operating loss of $31.76 million.
Product revenue rose to $53.26 million, reflecting Papzimeos commercial sales following FDA approval in August 2025.
SG&A expense increased 37.9% to $22.25 million, driven by Papzimeos commercialization activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001356090-26-000030), on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Precigen returns to profit in Q2 FY26; revenue rises to $54.98 million

You may also like

Crypto prices

Precigen returns to profit in Q2 FY26; revenue rises to $54.98 million﻿

You may also like

Crypto prices

Precigen returns to profit in Q2 FY26; revenue rises to $54.98 million